Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2024 financial and operating results on Thursday, May 9, 2024, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, May 9, 2024, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2024 financial and operating results and to provide a business update.

Interested parties may access the conference call on May 9 th , 2024, by dialing (800) 715-9871 from the U.S. and Canada and should request the "Lineage Cell Therapeutics Call". A live webcast of the conference call will be available online in the Investors section of Lineage's website. A replay of the webcast will be available on Lineage's website for 30 days and a telephone replay will be available through May 15 th , 2024, by dialing (800) 770-2030 from the U.S. and Canada and entering conference ID number 1330332.

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel or "off-the-shelf," cell therapies to address unmet medical needs. Lineage's programs are based on its proprietary cell-based technology platform and associated development and manufacturing capabilities. From this platform, Lineage designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions similar or identical to cells found naturally in the human body. These cells are created by applying directed differentiation protocols to established, well-characterized, and self-renewing pluripotent cell lines. These protocols generate cells with characteristics associated with specific and desired developmental lineages. Cells derived from such lineages are transplanted into patients in an effort to replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, and to restore or augment the patient's functional activity. Lineage's neuroscience focused pipeline currently includes: (i) OpRegen, a retinal pigment epithelial cell therapy in Phase 2a development under a worldwide collaboration with Roche and Genentech, a member of the Roche Group, for the treatment of geographic atrophy secondary to age-related macular degeneration; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of spinal cord injuries; (iii) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; (iv) PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and (v) RND1, a novel hypoimmune induced pluripotent stem cell line being developed in collaboration with Eterna Therapeutics Inc. For more information, please visit www.lineagecell.com or follow the company on X/Twitter @LineageCell .

Lineage Cell Therapeutics, Inc. IR  
Ioana C. Hone
( ir@lineagecell.com )
(442) 287-8963

LifeSci Advisors  
Daniel Ferry
( daniel@lifesciadvisors.com )
(617) 430-7576

Russo Partners – Media Relations  
Nic Johnson or David Schull
( Nic.johnson@russopartnersllc.com )
( David.schull@russopartnersllc.com )
(212) 845-4242

News Provided by Business Wire via QuoteMedia

LCTX:US
The Conversation (0)
Lineage to Present at 2024 BIO International Convention

Lineage to Present at 2024 BIO International Convention

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company's CEO, Brian M. Culley, will present at the 2024 BIO International Convention , on Tuesday June 4 th , 2024, at 2:30pm in Theater 3. Company representatives are also hosting meetings with potential partners and collaborators to discuss opportunities for strategic alliances across Lineage's novel pipeline of cell therapy transplant programs. The BIO International Convention is the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world, and is taking place June 3-6, 2024, at the San Diego Convention Center in San Diego, CA.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium

Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium

  • Persons with Lived Experience Session Expanded to Include Michaela & Kyle Devins
  • Clinical Session Expanded to Include Neuralink
  • Preclinical Session Expanded to Include Axonis, Novoron, Sania & Rewire Medical

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced updates to its 2 nd Annual Spinal Cord Injury Investor Symposium ("2 nd SCIIS"). The 2 nd SCIIS aims to accelerate development in SCI research and treatments by bringing together companies working in the development of treatments for SCI, with regulators, key opinion leaders, persons with lived experience, patient and community advocacy organizations, and the investment community, in order to discuss perspectives on current and future treatment alternatives, impact and support SCI disease awareness and clinical trial participation through the implementation of patient appropriate clinical endpoints, and broaden awareness of and investment of capital into SCI.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

  • Established New Services Agreement with Genentech to Support Ongoing Development of the OpRegen ® Program
  • Long-Term Visual Benefits from a Single Administration with OpRegen Reported at 2024 Retinal Cell & Gene Therapy Innovation Summit
  • OpRegen Preclinical Results Presented at 2024 Association for Research in Vision and Ophthalmology Annual Meeting
  • OPC1 Clinical Study Start Up Preparation Underway
  • Received CIRM Grant to Support 2 nd Annual SCI Investor Symposium
  • Appointed Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its first quarter 2024 financial and operating results and will host a conference call at 4:30 p.m. Eastern Time to discuss these results and to provide a business update.

"The quarter was highlighted by significant milestones and data updates on our lead program," stated Brian M. Culley, Lineage CEO. "A key area of attention for investors is our partnership with Roche and Genentech, and we are pleased to announce a new services agreement which reflects an additional commitment by Genentech for the benefit of the OpRegen program. We believe this agreement will enable our partners to take advantage of our cell transplant expertise to more fully investigate the promising potential of the OpRegen program and do so in a cost-effective manner. We also are planning to bring our second cell transplant program, OPC1, into the clinic this year for a condition with growing awareness of its unmet need and commercial opportunity. Lastly, we continue to build value through the advancement of our early-stage pipeline, which can help create value by capitalizing on the continued validation of our cell transplant approach."

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
OpRegen®  Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

OpRegen® Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

  • BCVA gains of +5.5 letters at 24 months in Cohort 4 patients (n=10)
  • BCVA gains of +7.4 letters among Cohort 4 patients with extensive OpRegen bleb coverage of the GA lesion (n=5)
  • Maintenance or increases in external limiting membrane (ELM) and retinal pigment epithelium (RPE) layers observed by optical coherence tomography (OCT) in patients with extensive bleb coverage of the GA lesion
  • Data suggests OpRegen may counteract RPE cell dysfunction and cell loss in GA by providing support to remaining retinal cells, with effects observed through at least 2 years following a single administration

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that 24 month visual acuity results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089 ) of RG6501 ( OpRegen ) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), were presented at the 2024 Retinal Cell & Gene Therapy Innovation Summit . The meeting was jointly organized by the Foundation Fighting Blindness and the Oregon Health & Science University Casey Eye Institute . The presentation, "OpRegen ® Retinal Pigment Epithelium (RPE) Cell Therapy for Patients with Geographic Atrophy (GA): Month 24 Results from the Phase 1/2a Trial," was presented by David Telander, MD, PhD , Retinal Consultants Medical Group, on behalf of Roche and Genentech , a member of the Roche Group.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2024 financial and operating results on Thursday, May 9, 2024, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, May 9, 2024, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2024 financial and operating results and to provide a business update.

Interested parties may access the conference call on May 9 th , 2024, by dialing (800) 715-9871 from the U.S. and Canada and should request the "Lineage Cell Therapeutics Call". A live webcast of the conference call will be available online in the Investors section of Lineage's website. A replay of the webcast will be available on Lineage's website for 30 days and a telephone replay will be available through May 15 th , 2024, by dialing (800) 770-2030 from the U.S. and Canada and entering conference ID number 1330332.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Bold Ventures Identifies New Gold Zone at Its Burchell Gold and Copper Property

Bold Ventures Identifies New Gold Zone at Its Burchell Gold and Copper Property

Bold Ventures Inc. (TSXV: BOL) (the "Company" or "Bold") is pleased to announce that it has received assays up to 56.9 gt gold (Au) from a newly identified zone at its Burchell Property ("the Property"), sampled during a prospecting and field reconnaissance program in November of this year. The high-grade sample was collected approximately 15 meters southwest of 2023 samples which returned between 0.04 and 0.51 gt Au. The zone has now been named the 111 (one-eleven) Zone. A geological sketch map of the outcrop exposure was made and three grab samples were collected along or near the zone during the 2024 program (see Table 1 below for coordinates, descriptions, and results). Assay results ranged from

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Vertex Minerals Limited  Power-up Gravity Gold Plant at Reward

Vertex Minerals Limited Power-up Gravity Gold Plant at Reward

Perth, Australia (ABN Newswire) - Vertex Minerals Limited (ASX:VTX) (OTCMKTS:VTXXF) is pleased to announce an update on the Reward Gold mine start up, with powering the plant up now completed and mechanical commissioning underway.

The processing facility rebuild, refurbishment and installation has progressed safely, efficiently and to plan, with the focus now turning to dry and wet commissioning of the respective operating circuits.

HIGHLIGHTS

- Vertex power up the newly installed Gravity Gold plant at the Reward Gold Mine.

- The Power generation units have now been installed and plugged into the Gravity plant.

- The plant components are now all installed and connected electrically.

- Completion of the dry stack tailing storage facility and tailings pipework installation.

- The plant can now be started up and mechanically tested and operated.

- Wet commissioning and ore feed commissioning will follow.

- Ore Sorter installation will be a retrofitted in early January

- Commissioning will be with stockpiled gold ore located alongside the gold plant

Vertex's Executive Chairman, Roger Jackson, said: "On time and within budget, the refurbishment and installation activities at the Reward gravity gold processing plant are almost complete with power up testing now underway. Our focus is now switching to dry and wet commissioning in the lead up to first gold next month. This is an exciting milestone for the company given the quality of the plant and the low capex required to get to this stage".

The Reward gold mine is well placed for a simple start -up:

- The new processing plant has been installed adjacent to the underground mine portal (640 Level) and over the existing footprint of the existing plant

- The 640 Level extends into the resource and no stripping required.

- Second egress in place with existing ladder way from 640 Level to surface.

- Some underground fleet and utility services are already owned by Vertex. With new fleet arriving.

*To view photographs, please visit:
https://abnnewswire.net/lnk/B92995G8



About Vertex Minerals Limited:  

Vertex Minerals Limited (ASX:VTX) is an Australian based gold exploration company developing its advanced Hargraves and Hill End gold projects located in the highly prospective Eastern Lachlan Fold Belt of Central West NSW. Other Company assets include the Pride of Elvire gold project and Taylors Rock gold/nickel/lithium project both located in the Eastern Goldfields of WA. The focus of Vertex Minerals is to advance the commercial production of gold from its NSW projects embracing an ethical and environmentally sustainable approach.



Source:
Vertex Minerals Limited

News Provided by ABN Newswire via QuoteMedia

Keep reading...Show less
Osisko Metals Announces Closing of C$107.4 Million "Bought Deal" Private Placement

Osisko Metals Announces Closing of C$107.4 Million "Bought Deal" Private Placement

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Osisko Metals Incorporated (the " Company " or " Osisko Metals ") (TSX-V: OM; OTCQX: OMZNF; FRANKFURT: OB51) is pleased to announce that it has closed its previously-announced "bought deal" brokered private placement offering (the " Offering ") for aggregate gross proceeds of C$107.4 million, including the partial exercise the option granted to the Underwriters (as defined herein). In connection with the Offering, the Company issued an aggregate of (i) 70,326,229 flow-through units of the Company (" FT Units ") consisting of 64,215,117 FT Units at an issue price of C$0.50 per FT Unit and 6,111,112 FT Units at an issue price of C$0.54 per FT Unit, for aggregate gross proceeds of C$35,407,558.98 and (ii) 277,051,466 units of the Company (" HD Units ") at a price of C$0.26 per HD Unit, for aggregate gross proceeds of C$72,033,381.16.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Noble Minerals Announces Update to Drilling Results from Noble Minerals-Canada Nickel Joint Venture on Mann Twp

Noble Minerals Announces Update to Drilling Results from Noble Minerals-Canada Nickel Joint Venture on Mann Twp

(TheNewswire)

Noble Mineral Exploration Inc.

Highlights

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×